|1.||Worcel, Manuel: 14 articles (12/2014 - 06/2002)|
|2.||Taylor, Anne L: 14 articles (12/2014 - 06/2002)|
|3.||Cohn, Jay N: 12 articles (12/2014 - 06/2002)|
|4.||Tam, S William: 11 articles (12/2014 - 12/2005)|
|5.||Taja-Chayeb, Lucia: 10 articles (10/2014 - 05/2003)|
|6.||Sabolinski, Michael L: 10 articles (08/2012 - 12/2005)|
|7.||Yancy, Clyde W: 9 articles (12/2014 - 06/2002)|
|8.||Sunagawa, Kenji: 7 articles (04/2015 - 01/2007)|
|9.||Shi, Riyi: 7 articles (04/2014 - 07/2006)|
|10.||Candelaria, Myrna: 7 articles (06/2012 - 01/2006)|
10/28/2005 - "Association of hydralazine with nitrova-sodilators has long been known to be beneficial in the vasodilator treatment of heart failure. "
09/01/1982 - "Thus long-term vasodilator treatment with hydralazine alone is not significantly more effective than placebo in chronic heart failure."
08/01/1978 - "It has been shown that hydralazine is beneficial in chronic heart failure by virtue of its afterload reducing effect. "
07/01/2014 - "Consequently, in the African-American Heart Failure Trial (A-HeFT) in self-identified black patients with symptomatic HF, adding a fixed-dose combination ISDN-hydralazine to modern guideline-based care improved outcomes versus placebo, including all-cause mortality, and led to early trial termination. "
10/01/1984 - "Clinical efficacy of hydralazine in chronic heart failure: one-year double-blind placebo-controlled study."
|2.||Hypertension (High Blood Pressure)
12/01/1983 - "N, and especially B + N, provided an efficacious once-daily treatment for systemic hypertension, and addition of hydralazine was effective in most nonresponders."
01/01/2011 - "Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. "
01/01/2010 - "Hydralazine may reduce blood pressure when compared to placebo in patients with primary hypertension, however this data is based on before and after studies, not RCTs. "
01/01/1983 - "Twenty patients with essential hypertension difficult to control on a combination of beta blocker, diuretic and vasodilator (mainly hydralazine) drugs were subject to an open study. "
04/04/1953 - "[Hydrazinophthalazine in hypertension; clinical studies]."
06/15/1994 - "Meanwhile, the therapeutic efficacy of hydralazine and heat was correlated with the changes in tumor blood flow, first of all with the delayed effects. "
06/15/1994 - "This study was aimed to assess the dependence on tumor size and blood flow of the efficacy of a vasoactive drug hydralazine with thermoradiotherapy. "
10/01/1989 - "In addition to cessation of perfusion in individual vessels, hydralazine eliminated flow in large patches of vasculature distributed non-uniformly throughout the tumor. "
03/01/2009 - "The purpose of this study was to evaluate the effects of hydralazine on APC reactivation and the inhibition of human cervical cancer cells in vitro. "
01/01/1992 - "Studies with mouse tumors have shown that the effectiveness of certain chemotherapeutic agents can be enhanced if they are used in appropriate combination with an anti-hypertensive drug such as hydralazine. "
07/01/2015 - "Salt-induced fibrosis persisted after normalization of BP with hydralazine. "
04/01/2012 - "Furthermore, the beneficial effects of hydralazine were observed while maintaining RAS activation, suggesting that the mechanism of fibrosis is blood pressure dependent."
04/01/2012 - "We provide evidence that myocardial infiltration by fibroblast progenitor cells secondary to AngII and the resultant fibrosis can be prevented by the addition of hydralazine. "
11/10/1998 - "Treatment with hydralazine had little or no effect on LVH and cardiac fibrosis and did not modify inducibility of ventricular arrhythmias by PES. "
03/01/2010 - "However, attenuation of cardiac fibrosis by hydralazine could be beneficial in the management of cardiac diseases."
12/01/2009 - "In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1α (HIF-1α) levels in experimental animal systems. "
09/01/1990 - "The present studies evaluated whether increasing the level of hypoxia in the tumour tissue, by treatment with the vasoactive agent hydralazine, could modify the chemosensitising ability of nitroheterocyclics. "
01/01/2008 - "We conclude that hydralazine increases the sensitivity of the ventilatory response to hypoxia, but lacks any effect on the pulmonary vasculature at the dose studied. "
01/01/2008 - "Recent hydralazine: (1) decreased diastolic blood pressure; (2) increased heart rate and cardiac output in euoxia and hypoxia whilst having no effect on delta Pmax; and (3) increased the ventilatory sensitivity to hypoxia. "
01/01/2005 - "In contrast, N2 breathing to terminal anoxia and intravenous hydralazine produced a negligible increase in Hb, but large reductions in HbO and HbT. "
|1.||Isosorbide Dinitrate (Isordil)
|3.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|5.||Vasodilator Agents (Vasodilators)
|1.||Drug Therapy (Chemotherapy)
|5.||Cesarean Section (Caesarean Section)